Allogeneic hematopoietic cell transplantation; the current renaissance

Copelan, Edward A.; Chojecki, Aleksander L.; Lazarus, Hillard M.; Avalos, Belinda R.

doi:10.1016/j.blre.2018.11.001

Cited by 87 publications

(64 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy in people with malignant and other blood disorders ( Copelan et al, 2019 ). However, GVHD, in which donor immune cells damage and destroy host tissues occurs in up to 30% of HSCT recipients, leading to severe morbidity and high rates of death ( Zeiser and Blazar, 2017 ).…”

Section: Purinergic Signaling In Gvhd In Humanized Nsg Micementioning

confidence: 99%

Use of Humanized Mouse Models to Investigate the Roles of Purinergic Signaling in Inflammation and Immunity

Sluyter

Watson

2020

Front. Pharmacol.

View full text Add to dashboard Cite

Section: Purinergic Signaling In Gvhd In Humanized Nsg Micementioning

confidence: 99%

Use of Humanized Mouse Models to Investigate the Roles of Purinergic Signaling in Inflammation and Immunity

Sluyter

Watson

2020

Front. Pharmacol.

View full text Add to dashboard Cite

“…Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a well-established treatment for a variety of hematologic malignancies, immune disorders and metabolic diseases [1]. Allo-HSCT often represents the only possible curative therapy, however it is hampered by high morbidity and mortality rates for an array of complications, including bloodstream infection and graft-versus-host disease (GvHD) [2]. Recently, the gut microbiome (GM) has emerged as a major contributor to the genesis of these complications and to transplant outcomes [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Microbiome-Derived Metabolites in Allogeneic Hematopoietic Stem Cell Transplantation

Masetti¹,

Zama²,

Leardini³

et al. 2021

IJMS

View full text Add to dashboard Cite

The gut microbiome has emerged as a major character in the context of hematopoietic stem cell transplantation. The biology underpinning this relationship is still to be defined. Recently, mounting evidence has suggested a role for microbiome-derived metabolites in mediating crosstalk between intestinal microbial communities and the host. Some of these metabolites, such as fiber-derived short-chain fatty acids or amino acid-derived compounds, were found to have a role also in the transplant setting. New interesting data have been published on this topic, posing a new intriguing perspective on comprehension and treatment. This review provides an updated comprehensive overview of the available evidence in the field of gut microbiome-derived metabolites and hematopoietic stem cell transplantation.

show abstract

“…Allogeneic hematopoietic stem cell transplantation (allo-HSCT) provides curative therapy for patients with malignant and nonmalignant hematologic disorders 1 , 2 . However, allo-HSCT is a highly aggressive and demanding medical supports with a significant risk of mortality 3 . Besides primary hematologic disorder and disease relapse after transplantation, transplant-related mortality is an important obstacle influencing treatment outcome of allo-HSCT 4 .…”

Section: Introductionmentioning

confidence: 99%

Pre-transplant depression decreased overall survival of patients receiving allogeneic hematopoietic stem cell transplantation: a nationwide cohort study

Wang

Park

Kim

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Studies investigating association of depression with overall survival (OS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) yielded conflicting results. A nationwide cohort study, which included all adult patients [n = 7,170; depression group, 13.3% (N = 956); non-depression group, 86.7% (N = 6,214)] who received allo-HSCT from 2002 to 2018 in South Korea, analyzed risk of pre-transplant depression in OS of allo-HSCT. Subjects were followed from the day they received allo-HSCT, to occurrence of death, or last follow-up day (December 31, 2018). Median age at allo-HSCT for depression and non-depression groups were 50 and 45 (p < 0.0001), respectively. Two groups also differed in rate of females (depression group, 55.8%; non-depression group, 43.8%; p < 0.0001) and leukemia (depression group, 61.4%; non-depression group, 49.7%; p < 0.0001). After a median follow-up of 29.1 months, 5-year OS rate was 63.1%. Cox proportional-hazard regression evaluated an adjusted risk of post-transplant mortality related to depression: OS decreased sequentially from no depression (adjusted hazard ratio [aHR] = 1) to pre-transplant depression only (aHR = 1.167, CI: 1.007–1.352, p = 0.04), and to having both depression and anxiety disorder (aHR = 1.202, CI: 1.038–1.393, p = 0.014) groups. Pre-transplant anxiety (anxiety only) did not have significant influence in OS. Additional medical and psychiatric care might be necessary in patients who experienced depression, especially with anxiety, before allo-HSCT.

show abstract

Allogeneic hematopoietic cell transplantation; the current renaissance

Cited by 87 publications

References 96 publications

Use of Humanized Mouse Models to Investigate the Roles of Purinergic Signaling in Inflammation and Immunity

Use of Humanized Mouse Models to Investigate the Roles of Purinergic Signaling in Inflammation and Immunity

Microbiome-Derived Metabolites in Allogeneic Hematopoietic Stem Cell Transplantation

Pre-transplant depression decreased overall survival of patients receiving allogeneic hematopoietic stem cell transplantation: a nationwide cohort study

Contact Info

Product

Resources

About